Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection
|
|
- Lynn Parsons
- 5 years ago
- Views:
Transcription
1 Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant, MD, Sonia Blandin, MD, Isabelle Arnaud, MD, Pascal Roy, MD, Laurence Geriniere, MD, and Pierre-Jean Souquet, MD Department of Thoracic Oncology and Chest Disease, Thoracic Surgery Unit, and Department of Biostatistics, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite, France Background. Neoadjuvant chemotherapy before resection of nonsmall cell lung cancer seems to increase survival, mainly in the early stage. Risks of postoperative complications after chemotherapy and surgery remain controversial. Here we review our experience with patients treated in one thoracic surgery center. Methods. undergoing resection for nonsmall cell lung cancer after induction chemotherapy between January 1993 and March 2002 were reviewed. Data collected included age, sex, preoperative forced expiratory volume in 1 second (FEV 1 ), hemoglobin, and arterial oxygen pressure tension (PaO 2 ), postoperative complications, and global survival.the main objectives were postoperative mortality and morbidity. Postoperative mortality and morbidity were defined as complications or deaths occurring within 30 days after surgery. Predictive morbidity factors were identified by univariate and multivariate analysis and overall survival by the Kaplan- Meier method. Results. In all, 114 patients were reviewed. Different induction chemotherapies were used, mainly cisplatin with vinorelbine or gemicitabine. Postoperative mortality was 2 of 114, 1 of 27 after pneumonectomy, and there were no deaths after lobectomy. Complications occurred in 29% of patients (33 of 114), usually infectious pneumonia and anemia requiring transfusion. Preoperative FEV 1, hemoglobin, and PaO 2 are not associated with morbidity in univariate or multivariate analysis. Conclusions. Preoperative chemotherapy does not increase postoperative mortality and morbidity after nonsmall cell lung cancer surgery, performed exclusively by thoracic surgeons. (Ann Thorac Surg 2005;80:423 7) 2005 by The Society of Thoracic Surgeons Preoperative chemotherapy seems to increase survival rates in stage IIIA nonsmall cell lung cancer (NSCLC), but there have been few randomized studies and these have had a small number of patients [1, 2]. In the randomized study by Depierre and colleagues [3], an increased survival with neoadjuvant chemotherapy was observed in the early stage patients (IB and II), mainly through reduced metastatic relapse. Preoperative chemotherapy has become the standard treatment for N2 patients. The influence of induction chemotherapy on postoperative outcomes remains controversial. Depierre and colleagues [3] and a few retrospective studies [4, 5] showed increased postoperative complications after neoadjuvant chemotherapy. Here we sought to determine the incidence of surgical morbidity and mortality after preoperative chemotherapy or chemoradiation in our thoracic surgery unit. The main objective was to analyze postoperative mortality and morbidity (complications occurring in the 30 days after surgery). A secondary Accepted for publication Feb 9, Address reprint requests to Dr Perrot, Department of Thoracic Oncology and Chest Disease, Hospices Civils de Lyon, Pneumologie 1A, Secteur JC, Chemin du Grand Revoyet, Centre Hospitalier Lyon Sud, Pierre Benite, Cedex France; emilie.perrot@chu-lyon.fr. objective was to identify predictive factors of morbidity by univaried and multivaried analysis and overall survival by the Kaplan-Meier method. and Methods Subjects and Data Collected We made a retrospective study of all patients who received preoperative chemotherapy or chemoradiation before thoracotomy for resectable NSCLC from January 1993 to March All patients underwent thoracotomy exclusively by two thoracic surgeons in the thoracic surgery unit of the Lyon Sud Hospital Center. The majority of patients did not have mediastinoscopy, and the preoperative stage was determined mainly through a thoracic computer scan. Preoperative data collected included age, sex, stage, forced expiratory volume in 1 second (FEV 1 ), hemoglobin, and arterial oxygen pressure tension (PaO 2 ), form and number of chemotherapy sessions, and whether the patient had preoperative radiotherapy. Details of the surgical procedure were recorded. Postoperative data collected included the date and form of resection, the final pathologic stage, classified according to the by The Society of Thoracic Surgeons /05/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 424 PERROT ET AL Ann Thorac Surg CHEMOTHERAPY BEFORE NSCLC RESECTION 2005;80:423 7 Table 1. Preoperative and Postoperative Stages Stage ctnm ptnm IA 0 10 IB 9 19 Total 9/114 (8%) 29/114 (25%) IIA 0 3 IIB Total 14/114 (12%) 27/114 (23%) IIIA IIIB Total 91/114 (79%) 51/114 (44%) IV 0 7 Total 0 (0%) 7/114 (6%) International System for Staging Lung Cancer [6], length of hospital stay and thoracic drainage, and postoperative chemotherapy or radiotherapy. Postoperative complications occurring within the 30 days after surgery were recorded. Pneumonia, extrarespiratory infection, bronchopleural fistulas, pleural or parietal bleeding, anemia requiring transfusion, pulmonary embolism, respiratory failure and adult respiratory distress syndrome, prolonged drainage, cardiovascular complications, other complications, and death were noted. Statistical Methods Univariate analysis of factors associated with postoperative mortality and morbidity was performed fitting the unconditional logistic regression models of Breslow and Day [7]. Predictive complication factors reviewed were age, stage, preoperative FEV 1, PaO 2, and hemoglobin. Factors with a p value smaller than 0.20 (likelihood ratio test) were included in the multivariate analysis. Odds ratios were presented with corresponding 95% confidence intervals. Survival was estimated using Kaplan-Meier estimators. Survival curves were compared by log-rank tests. A multivariate analysis was performed fitting a Cox proportional hazard model [8]. Statistical tests (two-tailed) were considered as significant at the 0.05 level. Results Demographics We reviewed 114 patients, 100 men and 14 women, with a median age of 61 years (range, 25 to 74). Histologic tumor analysis detected 64 squamous cell carcinomas, 29 adenocarcinomas, 17 large cell carcinomas, and 4 large cell neuroendocrine carcinomas. The majority of patients had reached clinical stage III before induction therapy, and mediastinoscopy was not usually carried out. Neoadjuvant Treatments All patients received preoperative chemotherapy, cisplatine-vinorelbine in the case of 56 patients, cisplatinegemcitabine for 12 patients, carboplatine-vinorelbine for 5 patients, and other regimens. Twenty patients also Table 2. Postoperative Complications Complication No. of Comments Pneumonia 7 Extrapulmonary infection 0 Bronchopleural fistula 0 Pleural or parietal bleeding 5 Requiring transfusion Anemia requiring 6 Without hemorrhage transfusion Pulmonary embolism 0 Respiratory distress 3 No deaths Prolonged drainage 4 Cardiovascular 5 Auricular fibrillations, 5 complications Other 1 Urine retention Deaths 2 Hemorrhage and left pneumonia received preoperative radiation, usually for apical tumors, and received a dose of radiation of 40 Gy. Surgical Resection Forty-one lobectomies, 4 bilobectomies, 55 pneumonectomies (27 right pneumonectomies and 28 left pneumonectomies), 5 wedge resections, and 9 exploratory thoracotomies were performed. Pneumonectomy was the most common operation (48%). Complete mediastinal lymphadectomy was perfomed in all patients. The 9 patients who only had exploratory surgery had nonresectable tumors. Postoperative thoracic drainage lasted from 2 to 25 days, averaging 5 days; hospitalization lasted from 3 to 27 days, with an average of 11 days. Clinical and pathological tumor extensions are presented in Table 1. Postoperative Two of the 114 patients died. The first death, due to pneumonia, occurred 5 days after a right pneumonectomy, and postpneumonectomy mortality rate was 1 of 55. The second death, by hemoptysis, occurred 3 days after explorative thoracotomy. Because of the small number of deaths, we could not analyze predictive factors of mortality. Postoperative Morbidity Overall morbidity was 28.9%; 33 of the 114 patients had postoperative complications. The 2 deaths were included in the 33 because they had complications before death (pneumonia and massive hemoptysis). Complications are detailed in Table 2. The most common complications were pneumonia, anemia, and hemorrhage. Cardiovascular complications were usually auricular fibrillation. No bronchopleural fistulas were included in our series. The relationship between morbidity and the type of surgical resection is shown in Table 3. Twenty patients received preoperative radiotherapy and chemotherapy. Among those patients, 7 had postoperative complications. These patients complications were not statistically different compared with patients
3 Ann Thorac Surg PERROT ET AL ;80:423 7 CHEMOTHERAPY BEFORE NSCLC RESECTION Table 3. Postoperative and Morbidity by Type of Surgery Morbidity Type of Surgery No. of % No. of % Right pneumonectomy (n 27) Left pneumonectomy (n 28) Total after pneumonectomy (n 55) Lobectomy (n 45) Bilobectomy (n 4) Exploratory thoracotomy (n 9) Wedge resection (n 5) Total (n 114) without preoperative radiotherapy: 7 of 20 (35%) and 26 of 94 (27.6%), respectively (p 0.51). We analyzed age, stage, preoperative FEV 1, PaO 2, and hemoglobin as predictors of complications. The medians were 61 years for age, 80% for FEV 1, 11.8 kpa for PaO 2, and 11.5 for hemoglobin. The thresholds used were 60 years for age, I II versus III IV for stage, 80% of the theoretical value for FEV 1, 10 kpa for PaO 2, and 12 g/dl for hemoglobin. The univariate analysis demonstrated that postoperative morbidity was not higher among older ( 60 years) patients (odds ratio 1.55, confidence interval 0.67 to 3.55; p 0.301), more advanced stage patients (odds ratio 1.35, confidence interval 0.60 to 3.06; p 0.460), patients with lower FEV 1 (odds ratio 1.61, confidence interval 0.68 to 3.82; p 0.274), patients with lower PaO 2 (odds ratio 0.978, confidence interval 0.31 to 3.04; p 0.969), or patients with lower hemoglobin (odds ratio 0.907, confidence interval 0.39 to 2.06; p 0.815). None of these factors was included in multivariate analysis because all the p values were higher than Fig 1. Overall survival by the Kaplan-Meier method. Survival Overall survival rates, analyzed by the Kaplan-Meier method, are shown in Figure 1. One-year and 5-year survivals were 76.5% and 35.5%, respectively. We analyzed the influence of the preceding factors on survival by univariate and multivariate analysis. The stage and preoperative PaO 2 were the two factors that influenced survival among age, stage, preoperative FEV 1, PaO 2, and hemoglobin in univariate and multivariate analysis (p and 0.002, respectively). Comment Postoperative complications in relation to preoperative chemotherapy for NSCLC in randomized studies are summarized in Table 4 (postoperative morbidity was not specified in most studies). Postoperative mortality varies from 0% to 7.8%, and the study by Depierre and associates [3], which includes the largest number of patients, shows increased postoperative mortality in the group given chemotherapy. As is this study, other studies providing details on postoperative mortality and morbidity after preoperative chemotherapy are retrospective. The most important study is that by Martin and coworkers [4], who retrospectively analyzed 470 patients who had undergone preoperative chemotherapy before ablation of NSCLC. Postoperative mortality and morbidity were, respectively, 3.8% and 38%, and right pneumonectomy was a predictive complication factor in multivariate analysis. Roberts and associates [5] analyzed 34 patients operated on after preoperative chemotherapy; there were no deaths after surgery, and postoperative major complications were 47%. This study concludes that neoadjuvant chemotherapy increases perioperative complications. Bernard and colleagues [10] analyzed 64 patients who received preoperative chemotherapy: postoperative mortality and morbidity were, respectively, 2% and 24%, and neoadjuvant chemotherapy remained independently associated with postoperative complications in multivariate analysis (p 0.02). The results from studies analyzing postoperative mortality and morbidity outside all neoadjuvant treatment are summarized in Table 5. All these studies are retrospective. Postoperative mortality rates varied from 1.3%
4 426 PERROT ET AL Ann Thorac Surg CHEMOTHERAPY BEFORE NSCLC RESECTION 2005;80:423 7 Table 4. Postoperative Rates in Randomized Trials Author, Reference, Year Number of Postoperative in Surgical Group in Neoajuvant Chemotherapy Group Pass et al [9] Stage IIIA 0% 0% 0% Rosell et al [1] Stage IIIA 7% 7% 7% Roth et al [2] Stage IIIA 3% 6% 0% Depierre et al [3] 373 Stage IB, II, IIIA 7.8% 4.5% 6.7% to 6.6% for overall mortality, from 1.6% to 13.4% for death after pneumonectomy, and from 0.6% to 4% for death after lobectomy. The most frequently reported causes of death were respiratory distress, pneumonia fistulas, and pleural empyema. Table 5 shows clearly that both postoperative mortality and morbidity are higher after pneumonectomy. In our study, overall mortality was 1.8%, namely, 2 deaths among 114 patients, the one from massive hemoptysis 3 days after an exploratory thoracotomy and the other from pneumonia 5 days after a right pneumonectomy. It was noted that overall mortality and mortality rates after pneumonectomies are identical (1.8%). On the other hand, mortality after right pneumonectomies was higher at 3.7% (1 of 27) as well as after exploratory thoracotomies, which reached 11% (1 of 9). These percentages are of little value, however, owing to the small number of deaths. The rate of postoperative complications in our study reached 28.9% (33 of 114 patients), the most common complications being pneumonia, anemia with transfusion, and hemorrhage. The majority of patients had advanced stage cancers, as 79% were in preoperative clinical stage III. Postoperative mortality and morbidity rates in our study (1.8% and 28.9%, respectively) are identical to, or even less than, those in the majority of retrospective studies with or without preoperative chemotherapy. These figures are also less than those observed for patients operated on in the same unit without neoadjuvant treatment: of 2,238 NSCLC ablations, there were 57 deaths, or a total mortality rate of 2.7%. In addition, our results are very close to the postoperative mortality rate of patients who had resection of a NSCLC in the same thoracic surgery unit, without preoperative chemotherapy: of 2,210 patients operated on, there were 57 deaths, or a mortality rate of 2.7%. Several elements can perhaps explain the limited number of postoperative complications in our sample. First, all the patients in our study were operated on exclusively by thoracic surgeons. It was, in any case, noted that systematic ganglion curettage carried out by the surgeons in our study did not raise the mortality rate. The retrospective study by Silvestri and coworkers [21] carried out on 1,583 patients showed a higher postoperative mortality rate for patients operated on by general surgeons than for those operated on by specialist thoracic surgeons (5.3% against 3%, p 0.05). In addition, all patients in the study were operated on in a unit with a high number of thoracotomies performed (about 150 bronchial cancers operated on in a year). The study by Bach and colleagues [22], which included 2,118 patients operated on in 76 different hospitals, concluded that that there were lower complication rates in large centers (3% mortality, 20% morbidity) than in hospitals handling fewer procedures (6% mortality, 44% morbidity). One reason for the higher postoperative mortality in the study by Depierre and associates [1] is probably that it was a multicenter study, which included centers with variable inclusion levels, corresponding to teams with more or less training. In our study, thanks to the high number of surgical interventions per year, the teams of anesthetists, nurses, and physiotherapists were used to performing bronchial cancer surgery. Moreover, patients in our study did not go into the intensive care unit in the operating theaters and bene- Table 5. Postoperative and Morbidity Rates in 10 Retrospective Studies Without Neoadjuvant Therapy Author, Reference Year Number of Stage Overall After Pneumonectomy After Lobectomy Morbidity Ginsberg et al [11] ,200 All stages 3.7% 6.2% 2.9% Not specified Deslaurier et al [12] All stages 3.8% 27% Shah et al [13] Stage I and II 3.2% 1.6% 4.03% 6.7% Duque et al [14] All stages 6.6% 13.4% 4.4% 32.4% Wada et al [15] ,099 All stages 1.3% 3.2% 1.2% Not specified Joo et al [16] Only pneumonectomy 10.5% Myrdal et al [17] All stages 2.9% 5.7% 0.6% 30.8% Bernard et al [18] Only pneumonectomy 7% 38.3% Alexiou et al [19] Only pneumonectomy 6.8% 39% Licker et al [20] Only pneumonectomy 9.3% 47%
5 Ann Thorac Surg PERROT ET AL 2005;80:423 7 CHEMOTHERAPY BEFORE NSCLC RESECTION fited from intensive respiratory physiotherapy in the surgical unit. That would appear to be an important point for explaining the low incidence of complications: artificial ventilation time is shorter, the risk of postoperative nosocomial infections is probably less, and the patient s treatment is less invasive. The selection of patients probably also has a beneficial role: the majority of operating questions were asked during a multidisciplinary meeting of lung specialists, thoracic surgeons, radiologists, and pathologists. In addition, patients who benefited from preoperative chemotherapy were often young and generally in better health, whereas older patients or those with a performance status score of 2 or more were more likely to be operated on straightaway. Finally, the preoperative FEV 1, PaO 2, and hemoglobin values show that most patients had good respiratory function and were not anemic before the operation. In our study, none of the data collected preoperatively was found to be predictive of complication factors. who had received preoperative radiotherapy seemed to have more postoperative complications than others (35% against 28.9%, respectively), but this difference was not statistically significant. The thresholds that we chose (80% for FEV 1, 10 kpa for PaO 2, and 12 g/dl for hemoglobin) corresponded to the lowest normal limits for each value. Our analysis of the survival of 114 patients by the Kaplan-Meier method showed overall survival rates of 76% at 1 year and 35% after 5 years, rates that correspond more or less to survival at the IIB stage of the International System for Staging Lung Cancer [6], although our study contains 23% stage II and 44% stage III patients. Factors that influenced survival in our study are the stage (p 0.003) and preoperative PaO 2 with a limit of 10 kpa (p 0.002). The fact that stage influences survival confirms known data. On the other hand, the results concerning PaO 2 indicate increased vigilance with patients showing preoperative hypoxia. References 1. Rosell R, Gomez-Condina J, Camps C, et al. A randomized trial comparing chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330: Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer. J Natl Cancer Inst 1994;86: Depierre A, Milleron B, Morot-Sibilot D, et al. From the French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery 427 in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 2001;20: Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001;72: Roberts JR, Eustis C, Devore R, et al. Induction chemotherapy increases perioperative complications in patients undergoing resections for non-small cell lung cancer. Ann Thorac Surg 2001;72: Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The New World Health Organization classification of lung tumours. Eur Respir J 2001;18: Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ, No 32, Cox DR. Regression models and life tables. J R Stat Soc 1972;34: Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53: Bernard A, Ferrand L, Hagry O, et al. Identification of pronostic factors determining risk groups for lung resection. Ann Thorac Surg 2000;70: Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983;86: Deslaurier J, Ginsberg RJ, Piantadosi S, et al. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest 1994;106(Suppl):329 30S. 13. Shah R, Sabanathan S, Richardson J, et al. Results of surgical treatement of stage I and II lung cancer. J Cardiovasc Surg 1996;37: Duque JL, Ramos G, Castrodeza J, et al. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Ann Thorac Surg 1997;63: Wada H, Nakamura T, Nakamoto K, et al. Thirty day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998;115: Joo JB, DeBord JR, Montgomery CE, et al. Perioperative factors as predictors of operative mortality and morbidity in pneumonectomy. Am Surg 2001;67: Myrdal G, Gustafsson G, Lambe M, et al. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg 2001;20: Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001;121: Alexiou C, Beggs D, Rogers ML, et al. Pneumonectomy for non-small-cell lung cancer: predictors of operative mortality and survival. Eur J Cardiothorac Surg 2001;20: Licker M, Spiliopoulos A, Frey JG, et al. Risks factors for early mortality and major complications following pneumonectomy for non-small-cell lung cancer. Chest 2002;121: Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114: Bach PB, Cramer LD, Downey RJ, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med ;345:181 8.
Postoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationDoes chemotherapy increase the risk of respiratory complications after pneumonectomy?
Does chemotherapy increase the risk of respiratory complications after pneumonectomy? Francesco Leo, MD, a PierGiorgio Solli, MD, a Giulia Veronesi, MD, a Davide Radice, PhD, b Antonio Floridi, MD, a Roberto
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationRepeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Robert J. Cerfolio, MD, Ayesha S. Bryant, MSPH, Thomas S. Winokur, MD, Buddhiwardhan
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationExperience has proven that pneumonectomy is a safe
Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does Side Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William H. Warren, MD, Sanjib Basu, PhD, Sean C. Wightman,
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationSurvival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy
Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce
More informationTHE MAJORITY of patients with locally advanced lung
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pn2 Non Small-Cell Lung Cancer: A Multicenter Phase II Trial Daniel
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationPerioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer
Original Article Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer Jessica Glover 1, Frank O. Velez-Cubian 2, Kavian
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationParenchymal air leak is a frequent complication after. Pleural Tent After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect
Pleural After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect Alessandro Brunelli, MD, Majed Al Refai, MD, Marco Monteverde, MD, Alessandro Borri, MD, Michele Salati, MD, Armando
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationBasaloid Carcinoma of the Lung: A Really Dismal Histologic Variant?
Carcinoma of the Lung: A Really Dismal Histologic Variant? Dae Joon Kim, MD, Kil Dong Kim, MD, Dong Hwan Shin, MD, Jae Y Ro, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery,
More informationNeuroendocrine (NE) lung tumors represent a broad
Large Cell Neuroendocrine Carcinoma of the Lung: A 10-Year Clinicopathologic Retrospective Study Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio Annessi, MD, Innocenza Putrino, MD, Guglielmo Ferrari,
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationDespite recent advances in the treatment of non-small cell
ORIGINAL ARTICLE Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy A Review of 549 Consecutive Cases Stephen A. Barnett, MBBS,* Valerie W. Rusch, MD,* Junting
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationT he increasing incidence and poor survival of patients
710 LUNG CANCER Survival after resection for primary lung cancer: a population based study of 3211 resected patients T-E Strand, H Rostad, B Møller, J Norstein... See end of article for authors affiliations...
More informationThe prognostic relevance of classifying neuroendocrine
Large Cell Neuroendocrine Carcinoma and Large Cell Carcinomas With Neuroendocrine Morphology of the Lung: Prognosis After Complete Resection and Systematic Nodal Dissection Joseph Zacharias, FRCS (CTh),
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationPleomorphic carcinoma of the lung: which CT findings predict poor prognosis?
Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Poster No.: C-1887 Congress: ECR 2015 Type: Scientific Exhibit Authors: A. Fujisaki, T. Aoki, S. Kinoshita, Y. Hayashida, Y.
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationHigh postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer.
Eur Respir J 2002; 19: 141 145 DOI: 10.1183/09031936.02.00226202 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 High postoperative risk after
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationThe effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationSmall-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
More informationWine cup stoma anastomosis after extended sleeve lobectomy for central-type squamous cell lung cancer
Higuchi et al. Journal of Cardiothoracic Surgery (2019) 14:36 https://doi.org/10.1186/s13019-019-0857-3 CASE REPORT Open Access Wine cup stoma anastomosis after extended sleeve lobectomy for central-type
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationPneumonectomy has frequently been used for the
Risk Factors for Early Postoperative Complications After Pneumonectomy for Benign Lung Disease GENERAL THORACIC Xue-fei Hu, MD,* Liang Duan, MD,* Ge-ning Jiang, MD, Hao Wang, MD, Hong-cheng Liu, MD, and
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationLung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer*
Delays in the Diagnosis and Treatment of Lung Cancer* Eija-Riitta Salomaa, MD, PhD; Susanna Sällinen, BM; Heikki Hiekkanen, MSc; and Kari Liippo, MD, PhD Study objectives: This study was undertaken to
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationPrognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution
Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationL ung cancer takes more lives than any other cancer in the
991 LUNG CANCER Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude Trond-Eirik Strand, Hans Rostad, Ronald A M Damhuis, Jarle Norstein... See end of article
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationDespite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,
More informationPOINT: Operative risk of pneumonectomy Influence of preoperative induction therapy
Gaissert et al Point/Counterpoint POINT: Operative risk of pneumonectomy Influence of preoperative induction therapy Henning A. Gaissert, MD, Dong Yoon Keum, MD, Cameron D. Wright, MD, Marek Ancukiewicz,
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationNanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J.
Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,
More information